November 28th, 2011
Three experts weigh in on findings from the ATLAS ACS 2-TIMI 51 and ADOPT trials.
March 18th, 2011
In a series of blog posts on CardioExchange, Samuel Goldhaber, Director of the Venous Thromboembolism Research Group in the Cardiovascular Division at Brigham and Women’s Hospital, has been guiding us on best practices around dabigatran. Recently, he teamed up with Elaine Hylek, Director of the Thrombosis and Anticoagulation Service at Boston University School of Medicine, […]